The June 2017 issue of Pharmafocus is now live!
pharmafile | May 23, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, Pharmafocus, Roche, Takeda, UK, brexit, data management, market access, neurological disorders
The latest edition of Pharmafocus is available to read online now! In this special issue, we cover the latest developments in UK life sciences, the shocking cyber attack on the NHS, and speak to Janssen’s Global Therapeutic Area Head, Infectious Diseases and Vaccines to discuss the leaps and bounds being made in hepatitis research.
With just over two weeks to go until the UK general election, the NHS has taken centre stage as a core topic of debate, with life sciences organisations and political parties alike releasing their manifestos throughout May. Their common message is clear: the next government must raise support and ensure the future of the health service for patients and professionals. Catch up on the debate with our cover story.
In our data management feature, Ben Hargreaves investigates how pharmaceutical firms and clinical professionals can capitalise on the rapid and ongoing technological boom to reinvigorate the drug development process and provide quicker, safer access to drugs. Meanwhile, Matt Fellows examines the latest developments in the field of neurological disorders, and how the past decade of stagnation on new, innovative treatments could be coming to an end, thanks to some exciting new research developments.
In this special edition of Pharmafocus, you can find our Market Access special, containing expert insight on the latest developments affecting the journey of drugs from the clinic to patients in need, including exclusive interviews with the European Medicines Agency on life after Brexit, alongside expert commentary from Takeda, Roche and more!
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz …
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …